Incidence and Risk of Influenza in Myasthenic Patients
NCT03884777 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2019-03-21
Summary
Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis
In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.
Conditions
- Myasthenic Crisis
- Upper Respiratory Infection
Sponsors & Collaborators
-
Centre d'Investigation Clinique et Technologique 805
lead OTHER
Principal Investigators
-
Rania BOUNAB, Dr · Raymond Poincaré Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-01
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
More Related Trials
-
Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis
NCT03597373 ·Status: UNKNOWN
-
Myasthenia Gravis Registry in China
NCT06241521 ·Status: RECRUITING
-
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605 ·Status: UNKNOWN
-
Efficacy of Methotrexate in Myasthenia Gravis
NCT00814138 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers for Fatigue in Patients with Myasthenia Gravis
NCT06860347 ·Status: COMPLETED
-
Mycophenolate Mofetil in Myasthenia Gravis
NCT00285350 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
NCT01555580 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals
NCT06774937 ·Status: NOT_YET_RECRUITING
-
Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis
NCT06688253 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients
NCT05311904 ·Status: COMPLETED
-
Acupuncture in Myasthenia Gravis (AcuMG)
NCT05230082 ·Status: COMPLETED ·Phase: NA
-
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection
NCT04695379 ·Status: COMPLETED
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Prognosis and Progression of Myasthenia Gravis Patients
NCT04101578 ·Status: UNKNOWN
-
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
NCT04590716 ·Status: COMPLETED
-
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
NCT00987116 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843 ·Status: RECRUITING
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
NCT02950155 ·Status: COMPLETED ·Phase: PHASE3
-
Education Program in Myasthenia
NCT04714658 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT05332587 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study
NCT04941079 ·Status: UNKNOWN